Advertisement
Advertisement
U.S. markets close in 15 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0258+0.2208 (+7.87%)
As of 03:44PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.8050
Open2.7700
Bid2.9900 x 1100
Ask3.0000 x 1100
Day's Range2.6700 - 3.0789
52 Week Range2.4200 - 29.0000
Volume315,721
Avg. Volume4,556,269
Market Cap34.416M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VRAX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Virax Biolabs Group Limited
    Daily – Vickers Top Buyers & Sellers for 09/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    13 days agoArgus Research
View more
  • PR Newswire

    Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc.

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today that it has entered into a distribution agreement to market Monkeypox Virus Real-Time PCR Detection Kits with Cosmos Holdings Inc. (Nasdaq: COSM) ("Cosmos"), an international healthcare group headquartered in the United States and with subsidiaries in Greece and the United Kingdom. Pursuant to the agreement

  • PR Newswire

    Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit

    Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkey

  • Benzinga

    EXCLUSIVE: Newly Listed Virax Biolabs Launches Monkeypox Antigen Rapid Test

    Virax Biolabs Group Ltd (NASDAQ: VRAX) has announced the distribution of a Monkeypox Antigen Rapid Test Kit launched in the European markets accepting the CE mark. The specialized diagnostic kits can be found by contacting the company’s sales representatives. Founded in 2013, in July 2022, Virax Biolabs concluded its initial public offering of 1.35 million shares at $5.00 per share, for total gross proceeds of $6.75 million. The test kits are for use in point-of-care settings. They can help heal

Advertisement
Advertisement